What Kliacef Treats: Main Uses and Benefits

Kliacef is commonly used to help address bacterial infections across key domains. It may be indicated for treating a variety of conditions caused by susceptible bacteria, focusing on where symptoms may intensify temporarily. It is considered relevant for managing bacterial infections of the ear (otitis media), throat (tonsillitis, pharyngitis), lower respiratory tract (pneumonia, acute bronchitis exacerbations), urinary tract (cystitis, pyelonephritis), and skin.

---

Key Therapeutic Benefit

This medication is applied across therapeutic domains where additional symptomatic support is needed. It assists with managing symptom clusters that may become intense or disruptive, such as fever, chills, and severe localized discomfort. It supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort during symptomatic periods.

“It plays a role in managing symptoms that interfere with daily comfort and is used when conditions produce significant symptomatic burden.”

---

Quick Fact

Quick Fact: Symptom Support for Systemic Imbalance Kliacef helps manage the systemic imbalance and physical discomfort (like fever) that can accompany acute bacterial episodes, supporting the patient during acute episodes.

Regulatory References

1. DailyMed Cefaclor package insert

Kliacef (Cephalexin) is generally allowed for use in adults and pediatric patients over 1 year of age, provided no specific contraindications or restrictions apply. Eligibility for this medicine is strictly defined by two main categories: absolute contraindications and conditions requiring special caution, as outlined in official regulatory documents.

Populations Who Must Not Use Kliacef (Contraindicated)

The medicine is formally contraindicated in any patient with a known allergy (hypersensitivity) to Kliacef (Cephalexin) or to any other drug within the cephalosporin class of antibiotics. Use in these patients presents a serious safety risk.

Populations Requiring Special Caution

Official labeling requires caution and clinical consideration for several patient groups:

• Penicillin Allergy: Patients with a history of allergy to penicillins or other beta-lactam drugs must be assessed carefully due to the documented risk of cross-hypersensitivity.
• Renal Impairment: Patients with markedly impaired kidney function (creatinine clearance < 30 mL/min) require special monitoring, as the drug is substantially excreted by the kidneys and safe dosage may be lower.
• Gastrointestinal Disease: Caution is needed for those with a history of gastrointestinal issues, especially colitis.
• Pregnancy and Lactation: While categorized as Pregnancy Category B, caution is advised when prescribing to pregnant or nursing mothers, as the drug is present in breast milk.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Kliacef (Cefaclor) across specific pharmacokinetic and pharmacodynamic domains.

---

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Category	Regulatory-Aligned Description
Probenecid (Uricosuric)	A renal transporter interaction occurs: Probenecid inhibits the renal tubular secretion of Cefaclor, resulting in increased and prolonged Cefaclor serum concentrations and overall higher exposure.
Oral Anticoagulants (e.g., Warfarin)	A pharmacodynamic interaction may enhance the anticoagulant effect, potentially leading to increased prothrombin time. This is attributed to the suppression of intestinal flora and possible inhibition of Vitamin K synthesis.
Antacids (Aluminum or Magnesium)	These substances reduce the extent of Cefaclor absorption when co-administered. For the extended-release tablet form, a timing rule dictates separation: the antacid must be taken one hour before or one hour after the Cefaclor dose.
Food	The rate of absorption is altered, but total absorption remains unchanged. Taking the drug with food reduces the peak plasma concentration ( C max) by 50% to 75%, and the peak is reached later.
Live Bacterial Vaccines	Cefaclor may decrease the therapeutic effect of vaccines such as the Typhoid vaccine.

---

Population-Specific Notes

In patients with renal impairment, the elimination half-life of Cefaclor is prolonged, from 0.6-0.9 hours to 2.3-2.8 hours. This pharmacokinetic alteration is noted in official labeling.

Kliacef (Cefaclor) functions exclusively as a bactericidal agent by attacking the core structure of susceptible bacterial cells. This action is rooted in two primary mechanistic domains that cascade into pathogen elimination.

Irreversible Blockade of Bacterial Cell Wall Synthesis

The drug's primary mechanism involves its beta-lactam structure binding covalently to Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the rigid peptidoglycan layer of the cell wall. This specific, irreversible inhibition permanently blocks the final cross-linking (transpeptidation) step in cell wall assembly. This molecular event is critical as it immediately sets the stage for cellular collapse and targets the microbial structure through the beta-lactam mechanism.

Osmotic Lysis and Pathogen Clearance

The failure to synthesize a stable cell wall results in the inability of the bacterial cell to contain its own high internal pressure. This molecular failure leads to osmotic lysis, where the cell wall ruptures, resulting in the rapid death and disintegration of the bacterium. This mechanism translates directly into the key physiological consequence of bactericidal clearance of the susceptible bacterial population.

Limitations Due to Microbial Defense

The mechanism can be rendered ineffective if bacteria acquire resistance, primarily through the production of beta-Lactamase enzymes that destroy the beta-lactam structure of Cefaclor. Alternatively, mutations that reduce the drug's binding affinity to the PBPs also severely constrain the mechanism's ability to trigger the bactericidal cascade.

Kliacef is an oral medicine that must be taken exactly as prescribed by your healthcare provider. Instructions for use depend on the specific form of the medicine (capsules, immediate-release, extended-release tablets, or oral suspension) and the intended duration of therapy.

Administration and Dosing

Formulation	Standard Adult Dosing	Administration Guideline
Capsule/Immediate-Release	250 mg to 500 mg every 8 hours	May be taken with or without food.
Extended-Release (ER) Tablet	375 mg to 750 mg every 12 hours	Should be taken with a meal or within one hour of eating. Do not crush, chew, or split the tablet.
Oral Suspension (Liquid)	20 to 40 mg/kg/day for children, divided into 8 or 12-hour doses	Shake the bottle well before each use to ensure the medicine is evenly mixed.

Key Procedural Instructions

• Duration of Therapy: The medicine must be taken for the full prescribed length of time, typically 7 to 10 days, even if symptoms improve. For infections caused by Group A beta-hemolytic streptococci, the course of treatment must be at least 10 days.
• Missed Dose: If a dose is missed, take it as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and continue with the regular schedule. Do not take two doses at once.
• Special Considerations: The dosage may require adjustment in patients with severe kidney impairment. Follow the specific instructions provided by your prescriber, especially regarding the total daily dosage and frequency.

Research Evidence / Overview of Studies for Kliacef

The available information about Kliacef (Cefaclor) comes from a variety of formal research studies, including Randomized Controlled Trials (RCTs) and comparative clinical trials. This research describes patterns observed when the medicine was evaluated in certain bacterial infections. It is important to remember that studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

---

Research Evidence for Ear and Throat Infections

Research exploring Kliacef's role in Acute Otitis Media (AOM), a common ear infection, primarily consists of comparative clinical trials. These studies focused on pediatric patients (children) and examined outcomes related to physical discomfort. Studies tracked how symptoms evolved in the observed populations and monitored the observed change in pathogen levels. Some early trials described the monitoring of pathogen levels and noted variability across different bacterial strains.

Similarly, in cases of Pharyngitis and Tonsillitis (throat infections), research has explored the drug's use in both adult and pediatric populations. Research monitored clinical improvement and measured changes in pathogen levels following the designated short-term treatment period. Researchers also examined patterns related to the recurrence or relapse of the infection. Research exploring long-term outcomes, particularly concerning the prevention of possible rare complications of S. pyogenes infection, is limited in modern comparative literature.

---

Evidence from Studies of Respiratory and Urinary Tract Infections

Research examined Kliacef's use in Lower Respiratory Tract Infections and Uncomplicated Urinary Tract Infections (UTIs). The evidence gathered suggested patterns observed in studies conducted during periods of increased symptom activity. Evidence remains limited and heterogeneous as much of this data is derived from older trials, and modern, large-scale comparative evidence is lacking against newer antibiotic classes for some conditions. Data suggest patterns related to symptom clearance and the measured recurrence rate over the short-term follow-up period.

---

Documented Evidence Gaps and Uncertainties

Despite the volume of historical research, certainty remains low in specific areas. Evidence quality varies across studies, with older trial designs sometimes lacking modern requirements. Long-term effects are not fully established, as follow-up durations were typically limited to the acute phase of illness. Comparative evidence is lacking in modern literature for some indications. Furthermore, limited data exist for certain groups, such as patients with markedly impaired renal function.

Key Studies & References

1. Cefaclor Label: Capsule and Oral Suspension (FDA Regulatory Document)
2. Cefaclor Extended-Release Tablets USP (DailyMed Package Insert) - Pharmacokinetic Differences

Common questions about Kliacef (FAQ)

Q: Is Kliacef considered a treatment that is usually taken long-term?

According to official product information, Kliacef is prescribed for a short duration of use to treat acute bacterial infections. The typical course of treatment is generally between 7 to 10 days, although this can vary based on the specific infection being addressed.

Q: Is it common to feel unusually tired or fatigued while taking Kliacef?

Official reports have rarely mentioned symptoms of tiredness or fatigue (sometimes called somnolence) in individuals taking Kliacef. It is noted that a clear cause-and-effect relationship between the medicine and these specific symptoms is not fully established.

Q: Do official reports mention mood changes or confusion as a possible side effect of Kliacef?

Regulatory documents indicate that certain rare effects involving the central nervous system (CNS) have been reported. These include feelings of confusion, agitation, or nervousness.

Q: What are the known restrictions for use in patients with a history of seizures?

Because the active ingredient in Kliacef, Cefaclor, has been associated with seizures in cases of overdose, official guidance indicates that caution is generally advised for patients with a history of seizure disorders.

Q: Is it described in product information that Kliacef can interact with alcoholic drinks?

Official product information does not list a specific formal drug-alcohol interaction for Kliacef. However, standard patient counseling information notes the importance of informing a healthcare provider about any regular alcohol use.

Q: Is Kliacef considered to be an addictive or habit-forming drug?

Kliacef is classified as a cephalosporin antibiotic. According to official classification, it is not listed as a controlled substance and is therefore not considered to be an addictive or habit-forming drug.

Q: Does Kliacef contain any form of steroids or similar compounds?

No, Kliacef is a cephalosporin antibiotic that works by targeting bacteria. The medication does not contain any steroids or similar compounds.

Q: What are the official recommendations if a person accidentally takes an extra dose of Kliacef?

If an extra dose is accidentally taken, official information states that potential overdose symptoms may include severe vomiting and, in rare instances, seizures. Regulatory documents state that immediate medical attention may be necessary in the event of an overdose.

Q: Are there any restrictions on operating machinery while taking Kliacef?

Due to the rare possibility of effects like dizziness or tiredness, official patient information advises caution with activities like driving or operating heavy machinery. Official information suggests caution is maintained due to the possibility of effects like dizziness or tiredness.

Q: Are there specific contraindications for use of Kliacef in the elderly population?

Official documents do not list a specific contraindication based solely on advanced age. However, because Kliacef is cleared by the kidneys, the dosage may require adjustment in patients with severe kidney impairment, a condition more commonly seen in older adults.

Q: What is the safety classification of Kliacef for individuals who are pregnant?

Kliacef is assigned Pregnancy Category B in official labeling. This classification means that animal reproduction studies have generally not shown a risk to the fetus. Official labeling states that studies in pregnant individuals have not been conducted.

Q: What information is available about Kliacef use for breastfeeding individuals?

According to regulatory information, the active ingredient Cefaclor is excreted in breast milk. For this reason, official guidance notes that caution should be considered when the drug is administered to a nursing woman.

Q: Why is Kliacef sometimes specifically instructed to be taken with food?

The guidance regarding food intake primarily relates to the Extended-Release (ER) tablet form. Official documentation states that taking the ER tablet with a meal is directed to help control the rate at which the medicine is absorbed, even though the total amount of medicine absorbed by the body remains the same.

Q: How is Kliacef handled in patients who have a known gastrointestinal disease?

Official prescribing information indicates that caution is advised when prescribing Kliacef to individuals with a history of gastrointestinal disease. This is particularly highlighted for patients with a history of colitis (inflammation of the colon).

The storage and disposal instructions for Kliacef (cefaclor) are specific to its form, as defined by regulatory labeling.

---

Official Storage and Handling

Temperature Requirements

Form	Storage Condition
Capsules/Tablets	Store at controlled room temperature (20 C to 25 C).
Reconstituted Suspension	Store in a refrigerator (2 C to 8 C). Do not freeze.

---

Stability, Protection, and Disposal

All forms must be kept in the original container, tightly closed, and protected from moisture and excessive heat. The reconstituted liquid suspension must be discarded after 14 days of refrigeration. All medication must be stored out of the sight and reach of children. Unused or expired Kliacef should be disposed of through a drug take-back program or official household disposal procedures.